KRYS — Krystal Biotech, Inc. catalysts
Next verified catalyst
2026-12-01 — A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12 (month) in 4mo
ESTIMATED |
READOUT
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic
Phase 1/2 · Neurotrophic Keratitis |
KRYS Krystal Biotech, Inc. | KB801 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-12 (month) in 4mo
ESTIMATED |
READOUT
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermo
Phase 3 · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa |
KRYS Krystal Biotech, Inc. | KB803 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|